Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin

Area of Science:

• Pulmonology
• Pharmacology
• Environmental Science

Background:

• Chlorofluorocarbons (CFCs) use in metered dose inhalers (MDIs) was phased out due to ozone depletion concerns.
• Hydrofluoroalkane (HFA) propellants, such as HFA-134a, have been developed as replacements.
• Albuterol reformulated with HFA-134a (Proventil HFA) is available for asthma treatment.

Purpose of the Study:

• To compare the efficacy of Proventil HFA against Ventolin, Proventil, and a placebo (HFA-134a) MDI.
• To assess the effectiveness in preventing exercise-induced bronchoconstriction in asthma patients.

Main Methods:

• A randomized, single-blind, placebo-controlled, 4-period crossover study.
• Twenty asthma patients received two puffs of study inhalers 30 minutes before a standardized exercise challenge.
• Spirometry, heart rate, blood pressure, and ECG were monitored post-exercise.

Main Results:

• Proventil HFA demonstrated efficacy comparable to Ventolin and Proventil in preventing FEV1 decline post-exercise.
• All active treatments were significantly more effective than placebo in preventing exercise-induced bronchoconstriction.
• A significantly lower percentage of patients experienced a >= 20% fall in FEV1 with active treatments compared to placebo.

Conclusions:

• Proventil HFA provides comparable protection against exercise-induced bronchoconstriction to existing albuterol inhalers.
• Proventil HFA exhibits a similar safety profile to Ventolin for preventing exercise-induced bronchoconstriction.
• HFA-134a reformulated albuterol is a viable and effective option for managing exercise-induced asthma symptoms.